维普中文期刊产品整合服务
320篇 您的检索式:作者名="BISCEGLIE"
    题名 作者 年代 出处 被引量
1Alterations of seminal and hormonal parameters:An extrahepatic manifestation of HCV infection?显示文摘瞄准:在精液的参数和繁殖神经质的浆液层次上评估 HCV 感染和相对抗病毒的处理的可能的影响。方法:有 HCV 相关的长期的肝炎和 16 个健康男志愿者的十个男病人被学习。在所有使精液的参数遭到(nemaspermic 集中,进步活动性,形态学) 并且神经质的层次被决定。精液的参数和抑制素 B,刺激滤泡的荷尔蒙, luteinizing,总数和免费睾丸激素,雌二醇,在病人的 prolactine 在六和 12 个月以后被测量抗病毒联合(interferon+ribavirin ) 治疗。结果:在治疗前的病人比控制象更低的抑制素 B 和免费睾丸激素层次一样显示出显著地更低的 nemaspermic 活动性和形态学。在情况中的抑制素 B 层次被改进在五个应答者的六和 12 瞬间术后疗法(161.9+/-52.8 pg/mL 对 101.7+/-47.0 pg/mL 和 143.4+/-46.1 pg/mL 对 95.4+/-55.6 pg/mL,分别地) 。病人的神经质的模式显著地没改变术后疗法,与有起始的减小和全面随后的增长(19.7+/-6.4 pg/mL 对 13.6+/-5.0 pg/mL 对 17.3+/-5.7 pg/mL ) 的雌二醇层次的例外。然而,在 1 年的应答者,免费睾丸激素(14.2+/-2.54 pg/mL 对 17.1+/-2.58 pg/mL ) 的重要增长发生了。nemaspermic 形态学的一个缺陷发生了,当另外的精液的参数没在抗病毒的治疗期间显著地变化时。结论:有 HCV 感染的病人比控制显示出更坏的精子的参数,建议精子发生上的病毒的可能的否定影响,与在抗病毒的治疗期间的进一步温和的缺陷。然而,治疗能改进精子的功能,由增加的抑制素 B 层次建议了并且在应答者改进了神经质的模式。进一步的研究被需要证实这些初步的吸引人的结果。Marilena Durazzo Alberto Premoli Cataldo Di Bisceglie Angela Bertagna Emanuela Fagà Giampaolo Biroli Chiara Manieri Simona Bo Gianfranco Pagano 2006World Journal of Gastroenterology2006,12,19:9
2Maintenance Peginterferon Therapy and Other Factors Associated With Hepatocellular Carcinoma in Patients With Advanced Hepatitis C显示文摘Anna S. Lok James E. Everhart Elizabeth C. Wright Adrian M. Di Bisceglie Hae–Young Kim Richard K. Sterling Gregory T. Everson Karen L. Lindsay William M. Lee Herbert L. Bonkovsky Jules L. Dienstag Marc G. Ghany Chihiro Morishima Timothy R. Morgan 2011Gastroenterology2011,,3:4
3Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease显示文摘Anna S. Lok Leonard B. Seeff Timothy R. Morgan Adrian M. di Bisceglie Richard K. Sterling Teresa M. Curto Gregory T. Everson Karen L. Lindsay William M. Lee Herbert L. Bonkovsky Jules L. Dienstag Marc G. Ghany Chihiro Morishima Zachary D. Goodman 2009Gastroenterology2009,,1:3
4Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions显示文摘Elizabeth M Brunt Christine G Janney Adrian M Di Bisceglie Brent A Neuschwander-Tetri Bruce R Bacon 1999The American Journal of Gastroenterology1999,,9:3
5Positron emission tomography scanning in the evaluation of hepatocellular carcinoma显示文摘M.Akram Khan Connie S Combs Elizabeth M Brunt Val J Lowe Michael K Wolverson Harvey Solomon Brian T Collins Adrian M.Di Bisceglie 2000Journal of Hepatology2000,,5:2
6Telbivudine Improves Renal Function in Patients With Chronic Hepatitis B显示文摘Edward J. Gane Gilbert Deray Yun-Fan Liaw Seng Gee Lim Ching-Lung Lai Jens Rasenack Yuming Wang George Papatheodoridis Adrian Di Bisceglie Maria Buti Didier Samuel Alkaz Uddin Sophie Bosset Aldo Trylesinski 2014Gastroenterology2014,,1:2
7Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions显示文摘Elizabeth M Brunt Christine G Janney Adrian M Di Bisceglie Brent A Neuschwander-Tetri Bruce R Bacon 1999The American Journal of Gastroenterology1999,,9:2
8Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune‐suppressing and anticancer drugs: Just the tip of the iceberg?显示文摘Adrian M. Bisceglie Anna S. Lok Paul Martin Norah Terrault Robert P. Perrillo Jay H. Hoofnagle 2015Hepatology2015,,2:2
9The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis <ce:link locator='fx1'/>显示文摘Arun J. Sanyal Robert J. Fontana Adrian M. Di Bisceglie James E. Everhart Michael C. Doherty Gregory T. Everson John A. Donovan Peter F. Malet Savant Mehta Muhammad Y. Sheikh Andrea E. Reid Marc G. Ghany David R. Gretch the HALT-C Trial Group 2006Gastrointestinal Endoscopy2006,,6:2
10Des-γ-Carboxy Prothrombin and α-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma显示文摘Anna S. Lok Richard K. Sterling James E. Everhart Elizabeth C. Wright John C. Hoefs Adrian M. Di Bisceglie Timothy R. Morgan Hae–Young Kim William M. Lee Herbert L. Bonkovsky Jules L. Dienstag 2010Gastroenterology2010,,2:2
11Design and endpoints of clinical trials in hepatocellular carcinoma显示文摘Llovet JM Di Bisceglie AM Bruix J 2008Natl Cancer Inst2008,100,10:1
12Design and endpoints of clinical trials in hepatocellular carcinoma 显示文摘Llovet JM Di Bisceglie AM Bruix J etal 2008Commentary JNCI2008,100,10:1
13New therapeutic strategies for hepatitis C显示文摘 McHutchison J Rice CM 2002Hepatology2002,35,:1
14Design and endpoints of clinical trials in hepatocellular carcinoma显示文摘Llovet J M Di Bisceglie A M Bruix J 2008J Natl Cancer Inst2008,100,:1
15Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment显示文摘Shiffman ML Di Bisceglie AM Lindsay KL 0,,:1
16Elevations in serum alpha- fetoprotein levels in patients with chronic hepatitis B 显示文摘Di Bisceglie A M Hoofnagle J H 1989Can- cer1989,64,10:1
17Complex odon toma: confocal laser scanning microscopy analysis of a case 显示文摘Crincoli V Scivetti M DI Bisceglie MB 2006MinervaStomatol2006,55,:1
18Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon显示文摘Di Bisceglie AM Shiffman NIL Everson GT 2008N EngI J Med2008,359,23:1
19Synthesis, characterisation, X-ray structure and biological activity of three new 5-formyluracil thiosemicarbazone complexes 显示文摘 Bisceglie F Pelosi G 2001J Inorg Biochem2001,83,23:1
20Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C显示文摘Di Bisceglie AM Ghalib RH Hamzeh FM 2011Viral Hepat2011,14,6:1
返回顶部 每页显示:
共16页 首页 上一页 第1页 下一页 末页 /16 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费